Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

How A et al. – The results provide compelling evidence that combined bevacizumab and 5–FU offers superior anti–fibrotic effect over monotherapy in a model of glaucoma filtration surgery, whilst prolonging bleb survival at the same time. A synergistic effect is suggested to be present.

Related Articles

Glaucoma and dry eye data from Germany
Ophthalmology Times Europe, 10/27/09    Relevance Score: 93%

Understanding the Importance of IOP Variables in Glaucoma
Survey of Ophthalmology, 10/23/09    Relevance Score: 92%

Characteristics of respondents with glaucoma and dry eye in a national panel survey
Clinical Ophthalmology, 11/13/09    Relevance Score: 91%

Gene-directed therapy in glaucoma may have future clinical applications
Ophthalmology Times Europe, 10/22/09    Relevance Score: 91%

Sequential Glaucoma Implants in Refractory Glaucoma
American Journal of Ophthalmology, 10/20/09    Relevance Score: 91%

Today in Clinical Pharmacology...keeping you current

Pharmacological and environmental factors in primary angle-closure glaucoma
British Medical Bulletin, 11/25/09

Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated With Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%
Retina, 11/25/09

Infliximab and anterior optic neuropathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 11/23/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address